Over the last three and a half years, Novartis Venture Fund has remade its team and narrowed its remit to early-stage opportunities in therapeutics. The fund’s 2020 exits suggest the strategic shift may...

Roche’s deal to acquire a clinical cystic fibrosis program from U.K.-based Enterprise delivers a return to the biotech’s shareholders while allowing the venture-backed company to continue development of another pipeline project. Roche (SIX:ROG; OTCQX:RHHBY) is...

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Tissue markers; gene profiling A study from Lily Yeh Jan and Yuh Nung Jan at UCSF suggests that tumor levels of TMEM16A could help predict survival in pancreatic cancer patients, and...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed...

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) on April 12 in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and...

Respiratory company Enterprise Therapeutics Ltd. (Falmer, U.K.) raised £29 million ($40.9 million) in a series B round led by Versant Ventures and Novartis Venture Fund. Also participating were new investor Forbion and existing investors Epidarex...

Enterprise Therapeutics Ltd.’s belief that it can improve on existing mucus-clearing therapies led an investor syndicate to back the respiratory company in a £29 million ($40.9 million) series B round. Versant Ventures and Novartis Venture...

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...

INDICATION: Cystic fibrosis (CF) Cell culture, patient sample and mouse studies suggest inhibiting the interaction of miR-9 with its negative regulator ANO1 could help treat mucus accumulation in CF. In bronchial epithelial cells from patients,...